Healthcare entity

Moderna Inc.

Company MRNA

They are less corroborated than the beat average, carrying 2 original sources each against 4.4 for the same window. market-trends accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. AlphaCore Wealth Advisory is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories.

Last mentioned: Jul 21, 2026

RSS updates
Share

Entity pulse

Recent coverage · Moderna Inc.

↑
3 stories
6.3 avg impact
33% positive
33% negative

Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.

  • 33% positive
  • 33% neutral
  • 33% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Moderna Inc.

They are less corroborated than the beat average, carrying 2 original sources each against 4.4 for the same window. market-trends accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. AlphaCore Wealth Advisory is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 128-day window averages about 0.2 stories each week. Their average consequence score of 6.3 sits level with the 6.3 recorded across the beat in that window. This profile follows 3 Healthcare stories mentioning Moderna Inc. across the period from March 16, 2026 to July 21, 2026.

Stories tracked
3
Per week
0.2
Sources per story
2

Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 440 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Moderna Inc.. Shared-story counts are live from our verified record — not editorial picks.

Key Data

ticker
MRNA
name
Moderna Inc.
price
112.5
change
-1.2
changePct
-1.05

Timeline

  1. Cramer Endorsement & 109% YTD Gain

    Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.

  2. Quarterly Update

    Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.

  3. Public Criticism

    Major editorials highlight the FDA's 'erratic' behavior as a threat to the broader innovation ecosystem.

  4. Refusal to File

    Senior regulator Vinay Prasad refuses to review Moderna's flu vaccine application, citing trial design concerns.

  5. Grants Rescinded

    The administration pulls back hundreds of millions in funding for mRNA-based research projects.

  6. Trial Design Support

    FDA officials reportedly signal support for Moderna's flu vaccine trial workaround and data submission plan.

  7. Post-Pandemic Decline

    Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.

  8. Peak Valuation

    Moderna reaches a market capitalization of $200 billion during the height of pandemic vaccine distribution.

  9. COVID Vaccine Success

    Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.

Stories mentioning Moderna Inc. 3

Moderna Inc. is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.